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Background: Castration-resistant prostate cancer (CRPC) is an incurable malignancy. Long noncoding RNAs
(lncRNAs) play key roles in drug resistance. Materials & methods: LncRNA HORAS5 role in cabazitaxel
resistance (i.e., cell-count, IC50 and caspase activity) was studied via lentiviral-mediated overexpression
and siRNA-based knockdown. Genes expression was analyzed with RNA-sequencing, reverse transcrip-
tion quantitative PCR (RT-qPCR) and western blot. HORAS5 expression was queried in clinical database.
Results: Cabazitaxel increased HORAS5 expression that upregulated BCL2A1, thereby protecting CRPC cells
from cabazitaxel-induced apoptosis. BCL2A1 knockdown decreased cell-count and increased apoptosis in
CRPC cells. HORAS5-targeting antisense oligonucleotide decreased cabazitaxel IC50. In CRPC clinical sam-
ples, HORAS5 expression increased upon taxane treatment. Conclusion: HORAS5 stimulates the expression
of BCL2A1 thereby decreasing apoptosis and enhancing cabazitaxel resistance in CRPC cells.
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Castration-resistant prostate cancer (CRPC) is an incurable malignancy [1]. It occurs when prostate cancer (PCa)
cells acquire mutations and other genetic and epigenetic alterations in the (androgen receptor) AR signalling and
in cell survival pathways; hence they stop responding to androgen deprivation therapies [2–4]. At this stage, next-
generation hormonal treatments such as enzalutamide and abiraterone and chemotherapy such as docetaxel and
cabazitaxel are the only effective treatment options [5–8]. In advanced CRPC stages, normally characterized by high
metastatic burden (mCRPC), cancer cells can become resistant to these treatments. At this stage mCRPC patients
median survival is very poor (1–2 years) [4], therefore novel therapeutic approaches to increase drug efficacy are
urgently needed.
Long noncoding RNAs (lncRNAs) are >200 bp transcripts that lack of protein-coding capacity and the majority
are still uncharacterized [9]. Due to their ability to fold into various structures [10], they could have several functions
and mechanisms of action inside the cells, some of which were recently described [11–14]. LncRNAs have been
investigated in health and disease and some of them were characterized as key players in cancer-associated pathways
such as development of metastatic status and drug resistance [15–19]. In the context of drug response, some studies
showed that lncRNAs can increase drug sensitivity in specific cancers. However, several lncRNAs have been shown
to promote resistance to various agents, such as hormonal therapy or chemotherapy agents [13,17,20,21].
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In a recently published study, we have characterized the lncRNA HORAS5 (i.e., linc00161) in PCa, showing
that it was upregulated in patient-derived xenografts (PDXs) models and increased the survival of AR+ CRPC
cells [22]. HORAS5 was already studied in osteosarcoma cells where it showed a proapoptotic oncosuppressive role
that determined the increase of cisplatin sensitivity via miR-645 inhibition and action in the IFIT2 pathway [13].
Despite this evidence, HORAS5 was then found to increase migration and invasion in hepatocellular carcinoma
patients and higher expression of this transcript correlated with poor prognosis [23]. A recent study also showed that
HORAS5 can promote drug resistance in ovarian cancer via acting as a competing endogenous RNA with another
miRNA in a different pathway (linc00161-miR-128-MAPK1 axis) [21]. All this evidence shows that HORAS5
modulates drug-associated response in different malignancies and that this transcript can have different functions
in different tissues.
Based on this evidence, we have decided to investigate whether HORAS5 plays a role in the drug response
of AR- and AR+ CRPC cells. For this purpose, we have tested a panel of clinically relevant drugs on CRPC
cells expressing different levels of this transcript [22]. We have shown that cabazitaxel was the only drug tested
that induced a significant, concentration-dependent increase in HORAS5 expression. Hence, we have decided
to further investigate the role of HORAS5 in cabazitaxel response. Our results suggest that HORAS5 activates a
BCL2A1-dependent mechanism of action, thereby inducing cabazitaxel resistance in CRPC cells.
Materials & methods
Cell culture
Human PCa LNCaP, DU145 and 22rv1 cell lines were purchased from the American-Type Culture Collection
(ATCC, ON, Canada). In particular, we have selected LNCaP cells, which express a mutated AR gene and grow in
castrate testosterone concentrations [24] and in DU145 cells, which are AR- and a model of anaplastic CRPC [25,26].
LNCaP cells were cultured in RPMI-1640 ATCC modification from GIBCO (cat# A1049101) and DU145 and
22rv1 cells (DU145-NC, DU145-OE, 22rv1-NC and 22rv1-OE; see below and in Supplementary Figure 4)
in RPMI-1640 from GIBCO (cat# 21875034), supplemented with 10% of fetal bovine serum (FBS) and 1%
antibiotics (penicillin and streptomycin). All the cell lines were cultured according to the protocols available from
the ATCC website. Cells were cultured at 37◦C in a 5% CO2-humidified incubator.
HORAS5 overexpression with lentiviral stable transduction
DU145 cells that express HORAS5 at undetectable levels were stably transfected with a lentivirus-derived particle
that induced HORAS5 overexpression (Genecopoeia, MD, USA, Cat# LPP-GS266B-Lv105-050). 7.0 × 104 AR-
Du145 and AR+ 22rv1 cells were first seeded in 24-well plates and were incubated overnight. The following day,
old media was replaced by media supplemented with polybrene (aka Hexadimethrine Bromide, Sigma Aldrich,
Gillingham, UK, Cat# H9268) at a final concentration of 8 μg/ml to increase transduction efficiency [27]. After
that, 5 μl of the purified human linc00161 (HORAS5) lentiviral particles (Titer: 1.37 × 108 TU/ml where 1
TU = 100 copies of viral genomic RNA) were added to the wells and incubated overnight. The following day,
the wells were washed with RPMI-1640 containing 10% FBS three-times and were subsequently left for 2 days to
reach confluence. 48- to 72 h post-transduction, cells were split one-in-two into six-well plates and were allowed
to adhere for 5–6 h prior to antibiotic selection using puromycin (Gibco, Loughborough, UK, Cat# A1113803).
Selection lasted for 2 weeks with media change every 3–4 days. To achieve high copy number, 3μg/ml of puromycin
was selected. These cells were called Du145-OE and 22rv1-OE, respectively, and were passaged and frozen for
long-term storage in liquid nitrogen. All overexpression experiments were normalized to cells transduced with the
empty vector (DU145-NC and 22rv1-NC, respectively) as lentiviral vectors did not induce phenotypic changes.
Total & subcellular-fractionated RNA extraction
Total RNA was extracted using the RNeasy plus mini Kit (Qiagen, Manchester, UK) from cultured cells according
to the manufacturer’s protocol.
Nuclear- and cytoplasmic-fractionated RNA extraction was performed on cultured cells using the PARIS™ kit
(Ambion, Loughborough, UK) following the manufacturer’s protocol. DNAse digestion of the fractionated RNA
was performed using the TURBO DNA-free™ Kit (Ambion, Cat# AM1907).
10.2217/epi-2019-0316 Epigenomics (Epub ahead of print) future science group
HORAS5 promotes taxane resistance in CRPC via a BCL2A1-dependent mechanism Research Article
Reverse-transcription & quantitative PCR
Upon extraction, 1 μg of total RNA was reverse-transcribed using high capacity cDNA reverse transcription kit
(Applied Biosystems, Loughborough, UK) following the kit instructions. The cDNA obtained was diluted ten-
times prior the quantitative PCR (qPCR). TaqMan assays (Applied Biosystems) were used for the qPCR to assess
gene expression as per the manufacturer’s protocol. The TaqMan assays used were LINC00161 (Hs00863167 g1)
and BCL2A1 (Hs00187845 m1). HPRT1 (Hs02800695 m1) was used as housekeeping control in all the reverse
transcription (RT)-qPCR experiments. For subcellular localization of RT-qPCR experiments, the probes MALAT1
(Hs00273907 s1) and GAPDH (Hs02786624 g1) were also used as nuclear and cytoplasmic control respectively.
siRNA-mediated gene knockdown
Gene knockdown (KD) experiments were performed using the reverse transfection method [28]. Cells were seeded
in six-well or 96-well plates with the lipid:siRNA mixture prepared using the RNAiMAX reagent (Invitrogen,
Loughborough, UK) according to the manufacturer’s protocol. Final siRNA treatment dosages were 2 nM con-
centrated. All duplexes were purchased from Integrated DNA Technologies (IDT) (Leuven, Belgium): anti-
HORAS5 (aka Linc00161) DsiRNA hs.Ri.LINC00161.13.2, anti-BCL2A1 DsiRNAs hs.Ri.BCL2A1.13.1 and
hs.Ri.BCL2A1.13.2 and nontargeting negative control (scramble) DS NC1. After 48 or 72 h post-transfection,
treated cells were harvested for extracting total RNA and/or total protein.
Drug treatments
5 mg of cabazitaxel (Jevtana, Selleckchem, Ely, UK, cat#S3022) was resuspended in dimethyl sulfoxide (DMSO)
in order to obtain a final stock solution of 5 mM. 5 mg of enzalutamide (MDV3100, Selleckchem, cat#S1250)
was resuspended in DMSO in order to obtain a final stock solution of 1 mM. Both drugs were stored at –80◦C.
Carboplatin was resuspended in water to obtain a stock solution of 10 mg/ml and stored at –20◦C. All drugs
were thawed at room temperature and diluted in cell culture media to treat the cells at different concentrations,
according to the experiments:
• Cabazitaxel was used to treat LNCaP and DU145 cells for 24–48–72 h at (5–50) nM in gene expression
experiments, caspase assays, RNA sequencing and at (000005–0.0005–0.05–0.5–5–50–100) nM in the Trypan
blue-based cell counting and IC50 calculation experiments. 22rv1 were treated for 48–72 h with 5–50 nM of
cabazitaxel in gene expression experiments and Trypan blue-based cell counting;
• Enzalutamide was used to treat LNCaP (1–10) μM and 22rv1 (10–100) μM cells for 72 h at in gene expression
experiments;
• Carboplatin was used to treat DU145 cells for 72 h at (1–10) μM in gene expression experiments. All concen-
trations selected were clinically achievable.
All the drugs concentrations have been selected based on the IC50 and concentrations used in the literature for
CRPC cells, following a log10 criteria, in order to select a wide range of concentrations for our analyses [29–32].
Trypan blue-based cell counting & IC50 calculation
Cell proliferation was assessed via Trypan blue-based cell counting; in this contest cell metabolic assays can give
altered results due to taxane interference with mitochondria metabolism [33].
2 × 105 DU145-NC and -OE (and 22rv1-NC and -OE, Supplementary Figure 4E) cells were seeded in a six-well
plate and treated with DMSO/cabazitaxel in the concentrations specified above (see drug treatments).
2.5 × 105 LNCaP cells and 5 × 105 DU145-OE cells were seeded in a six-well plate and reverse transfected
with 2 nM of control siRNA and either anti-HORAS5 siRNA or anti-BCL2A1 siRNAs, respectively. At day two
post-transfection, the cells were treated with DMSO/cabazitaxel in the concentrations specified above (see drug
treatments).
For all the cells, at day 3 (LNCaP) and 2 (DU145-NC/-OE and 22rv1-NC/-OE) after the drug treatment, trypan
blue-based cell counting was performed and the IC50 was calculated by nonlinear regression analysis (variable-slope
inhibitor fitting), after normalization to untreated (DMSO) cells.
Caspase activity assay
104 DU145-NC and -OE cells were seeded in a white, flat-bottom 96-well plate and treated with DMSO/5 nM
of cabazitaxel.
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1.25 × 104 LNCaP cells and 2.5 × 104 DU145-OE cells were seeded in a white, flat-bottom 96-well plate
and reverse transfected with 2 nm of control siRNA and either anti-HORAS5 siRNA or anti-BCL2A1 siRNAs,
respectively. At day 2 post-transfection, the cells were treated with DMSO/5 nM/50 nM of cabazitaxel.
At day 3 (LNCaP) and 2 (DU145-NC and -OE) after the drug treatment, Caspase-Glo reagent (Promega,
Southampton, UK) was added to the cells and total luminescence was quantified, following the manufacturer’s
protocol. Results were normalized to the cell count at the respective treatment concentration and time of treatment.
RNA sequencing & differential expression analysis
Total RNA samples were isolated from DU145-NC/OE cells untreated (DMSO) versus treated for 48 h with
5 nM of cabazitaxel. Next-generation sequencing (NGS) based on the Ion Torrent Semiconductor technology
(Thermo Fisher Scientific, Loughborough, UK) and bioinformatics analysis were carried out by the Institute of
Pathology of the University Hospital Basel, Switzerland. The resulting dataset was further analyzed to determine the
protein-coding genes upregulated when HORAS5 is overexpressed (DU145-OE) versus negative control (DU145-
NC) upon cabazitaxel treatment (cabazitaxel-driven genes in Figure 4A). The expression threshold was set as log2
fold-change >2 and p < 0.01 for the cells overexpressing HORAS5. The 87 genes were then filtered for DU145-NC
p-value and sorted in descending order (top 25 genes in Figure 4A). The final shortlist was obtained by ranking the
top three genes based on literature evidence on cancer and taxane resistance.
Protein extraction & western blot analysis
Cell lysates were obtained using 15–50–100 μl of radioimmunoprecipitation assay (RIPA) buffer (Tris pH 8.0
[Sigma Aldrich]; NaCl [Sigma Aldrich]; EDTA [Sigma Aldrich]; Igepal [Sigma Aldrich]; SDS [Sigma Aldrich],
NaF [Sigma Aldrich]; NaVO3 [Sigma Aldrich]) according to the number of cells used. Proteins were quantified
with the Peierce BCA assay (Thermo Fisher Scientific) as per the manufacturer’s protocol. 15 mg of proteins were
resolved via gel electrophoresis on reducing SDS-polyacrylamide gels (Tricine 10–20%, Thermo Fisher Scientific)
run at 110 V for 2 h. Protein transfer was performed using nitrocellulose membrane at 300 mA for 2.5 h. The
membranes were blocked in 8% skimmed milk dissolved in tris-buffered saline (TBS; Sigma Aldrich) containing
0.1% tween-20 (TBS-T) at room temperature for 1 h. After 1 h, the blots were incubated overnight at 4◦C
with protein-specific primary antibodies dissolved in 5% BSA diluted in TBS-T for anti-BCL2A1 (Cell Signalling
Technology, Leiden, The Netherlands, A1/Bfl-1 (D1A1C) Rabbit mAb, Cat# 14093) and 5% milk diluted in
TBS-T for anti-GAPDH (Sigma Aldrich, cat# G9545). After the overnight incubation, protein blots were washed
three-times with TBS-T for 10 min. Blots were then incubated with horseradish peroxidase (HRP)-conjugated
anti-rabbit secondary antibody (Thermo Fisher Scientific, cat#31460) dissolved in 8% milk diluted in TBS-T at
room temperature for 1 h. After the incubation, blots were washed four-times in TBS-T for 10 min each.
After washing, enhanced chemiluminescence (ECL) western blotting substrate kit was used (Millipore, Watford,
UK) to visualize blot chemiluminescence, using Syngene Gbox with GeneTools software (Syngene, Bangalore,
India).
CBioPortal analysis of clinical samples
To assess the clinical relevance of HORAS5 expression in PCa samples, CBioPortal (www.cbioportal.org) was
queried using a publicly available Agilent microarray dataset [34]. This dataset consisted of a single study with 63
patients, of which 15 patients did not undergo chemotherapy treatment and ten were treated with taxane only. We
compared none versus taxane only treatment.
Antisense oligonucleotides
1.5 × 105 LNCaP and 1.5 × 105 DU145-NC cells were seeded in six-well plates and after 24 h, the cells were
transfected with 2 nM of a negative control antisense oligonucleotides (ASOs) (Eurofins Genomics, Wolverhamp-
ton, UK, ASO-NC: C*C*T *T*C*C *C*T*G *A*A*G *G*T*T *C*C*T *C*C) and HORAS5-ASO3 (Eurofins
Genomics, HORAS5 V3*: G*G*C *T*G*C *T*G*C *A*T*G *T*C*T *A*C*A *G*T) preselected as the most
effective of eight tested ASO sequences for HORAS5 KD (Figure 6A), using the RNAiMAX reagent (Invitrogen,
Loughborough, UK), according to the manufacturer’s protocol. At day 2 post ASO treatment, the cells were treated
with DMSO/cabazitaxel at concentrations specified above (see drug treatments). At day 3 (LNCap) or day 2
(DU145-NC) postdrug treatment, the cells were counted using the tripan blue-based method.
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Figure 1. HORAS5 overexpression maintains its cytoplasmic location and does not affect cell proliferation and morphology. (A)
Schematic representation of the vector LPP-GS266B-Lv105-050 used to induce the expression of HORAS5 in the transduced cells (DU145).
The plasmid contains the long teminal repeat packaging elements, the citomegalovirus strong promoter, the pUC Ori bacteria-start
replication site and the antibiotic resistance cassettes to select the cells transduced and containing HORAS5. (B) qPCR expression of
HORAS5 (aka linc00161) in AR+ PCa cells with endogenous expression of the lncRNA (LNCaP) and AR- PCa cells with lentivector-induced
expression (DU145-OE). (C) qPCR expression of HORAS5 in the nuclear and cytoplasmic subcellular fractions of DU145-OE cells. GAPDH
and MALAT1 are used as controls for cytoplasmic and nuclear fractions, respectively. HPRT1 was used as housekeeping gene for data
normalization in all the qPCR experiments. (D & E) Pictures of DU145-WT, DU145-NC and DU145-OE cells` morphology (D) and MTS
proliferation curves of DU145-OE versus DU145-WT (E). The size bars in figure (D) represent 100 μm. Results expressed as means ± SD
from two independent replicates. Two-way ANOVA with Sidak’s post-test was performed for statistical comparison in (E).
AR: Androgen receptor; MTS: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; PCa: Prostate
cancer; qPCR: Quantitative PCR; SD: Standard deviation.
Statistical analysis
All data were obtained from at least two or three independent experiments and analyzed using GraphPad Prism 7
software. Values are presented as mean ± standard deviation (SD). Significant differences between the groups were
calculated using linear trend test, Student’s t-test, one-way ANOVA with Tukey’s multiple comparison post-test
and two-way ANOVA with Sidak’s multiple comparison post-test and nonlinear fit (log inhibitor vs normalized
response-variable slope) IC50 analysis. A p < 0.05 was set as threshold for statistical significance. Outlier test was
carried out to remove the extreme experimental replicate for the IC50 calculation.
Results
HORAS5 overexpression & sub cellular localization
Based on previously published data on HORAS5 expression in a panel of PCa cells [22], we selected LNCaP (AR+)
as cell line expressing this lncRNA and DU145 (AR-) as cell line with undetectable levels of HORAS5 [22]. To
investigate the effects of HORAS5 in AR- PCa cells, HORAS5 expression was artificially induced via DU145 cells’
stable transduction with lentiviral particles containing HORAS5 gene, expressed under the strong CMV promoter
(Figure 1A). This transduction induced elevated HORAS5 expression, which was stable for at least 20 passages
(Figure 1B). We called these cells DU145-OE and the corresponding cells transfected with the empty vector
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Table 1. Treatment selection based on clinical and in vitro evidence.
Cancer Type Clinical treatment used In vitro evidence Cell line miming
cancer
Treatment selected Ref.
AR+ CRPC Hormonal (abiraterone, enzalutamide) Active in AR+ CRPC cells LNCAP Enzalutamide [5,27,29]
Chemotherapy (docetaxel, cabazitaxel) Active in both AR+ and AR- CRPC cells Cabazitaxel [30,31]
AR− CRPC Chemotherapy (docetaxel, cabazitaxel,
platinum agents)
Active in both AR+ and AR- CRPC cells DU145 Cabazitaxel [30,31]
Platinum agents active in AR- CRPC cells Carboplatin [32,33]
AR: Androgen receptor; CRPC: Castration-resistant prostate cancer.
were called DU145-NC. Additionally, we have confirmed HORAS5 overexpression in AR+ 22RV1 cells, which
express undetectable endogenous levels of HORAS5 (Supplementary Figure 4A). Our previous studies showed
that HORAS5 is located in the cytoplasm of LNCaP cells [22]. Our results in DU15-OE cells indicate that the
artificial expression of this lncRNA preserved its cytoplasmic location (Figure 1C). Our analyses in 22rv1-OE also
confirmed HORAS5 cytoplasmic location (Supplementary Figure 4B). Additionally, we observed no morphological
changes induced by HORAS5 overexpression in DU145-OE versus DU145-NC and DU145-WT (Figure 1D) and
HORAS5 overexpression did not influence cell proliferation in untreated cells (Figure 1E).
HORAS5 expression is induced by cabazitaxel in a concentration- & time-dependent manner
Since our previous studies have shown HORAS5 upregulation in CRPC versus hormone sensitive PDXs [22] and
other studies suggested that HORAS5 modulates drug response [13,21], we sought to investigate whether exposure
to clinically employed drugs could affect the expression of HORAS5. To this aim, we selected three drugs, which
are representative of the most commonly used treatments in CRPC patients: the AR inhibitor enzalutamide, which
is used in AR+ CRPC [5,35,36]; the microtubule inhibitor cabazitaxel, which is active against both AR+ and AR-
CRPCs [37,38]; the platinum agent carboplatin, which displayed some activity in AR- CRPCs (Table 1) [39,40]. In
line with clinical indications, enzalutamide was used in LNCaP and 22rv1-OE cells, carboplatin in DU145-OE
cells only and cabazitaxel in all the cell lines with doses ranging around the IC50 and concentrations found in the
literature for CRPC cells, on a log10 basis [29–32]. Based on our criteria (p < 0.05 and R2 >0.5) enzalutamide did not
determine a significant change in HORAS5 expression in LNCaP (p = 0.2451, R2 = 0.06073) (Figure 2A) and 22rv1-
OE cells (p = 0.0029, R2 = 0.3195) (Supplementary Figure 4C) at the clinically achievable concentrations used [41].
Similarly, no effect was observed for carboplatin (p = 0.0061, R2 = 0.1657) (Figure 2B) [42,43]. Cabazitaxel induced
a concentration-dependent increase of HORAS5 expression in LNCaP (p < 0.0001, R2 = 0.6513) (Figure 2C),
DU145-OE (p < 0.0001, R2 = 0.7563) (Figure 2D) and 22rv1-OE cells (p < 0.0001, R2 = 0.7185) (Supplementary
Figure 4D). All the concentrations of cabazitaxel used in these experiments are clinically achievable [44]. Overall,
just cabazitaxel treatment determined a linear concentration-dependent increase in the expression of HORAS5
(R2 >0.5 linear trend test). A time-course experiment revealed that cabazitaxel-induced HORAS5 upregulation is
time-dependent: we did not observe any significant transcript upregulation up to 24 h after treatment. However,
HORAS5 was significantly upregulated in DU145 (48 h, 72 h) and in LNCaP (72 h) cells (Figure 2E & F). For
this reason, we chose 72 h for LNCaP and 48 h for DU145-OE as time points for further experiments.
HORAS5 modulation affects the proliferation & survival of PCa cells exposed to cabazitaxel
So far, we have shown that cabazitaxel induces a dose- and time-dependent increase in HORAS5 expression in
both AR+ and AR- CRPC cells. We therefore sought to investigate the functional significance of HORAS5 in
CRPC cells exposed to cabazitaxel. We optimized the silencing procedure and obtained a KD of 77%, at day
5 after transfection (Supplementary Figure 1A). This time point results from 2 days of silencing + 3 additional
days of cabazitaxel treatment. We then hypothesized that HORAS5 silencing and overexpression can affect CRPC
cell proliferation. We analyzed the effect of HORAS5 modulation on cabazitaxel anticancer activity. Our data
showed that cabazitaxel induced a dose-dependent growth inhibition (Figure 3A & B). This inhibition decreased
in DU145-OE compared with DU145-NC (Figure 3A) with a significant increase of cabazitaxel IC50 of 9.8-times
(from 3.11 ± 1.48 nM to 30.55 ± 3.9 nM, Supplementary Figure 1B) in the cells that overexpress HORAS5
(p = 0.0114) (Figure 3C). Vice versa, cabazitaxel-dependent growth inhibition increased in LNCaP cells upon
HORAS5 KD (Figure 3B). Our calculation showed that HORAS5 silencing caused dramatic decrease of cabazitaxel
IC50 in this cell line (from 20.80 ± 0.74 nM to 2.59 ± 0.77 nM, p = 0.0033) (Figure 3D, Supplementary Figure
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Figure 2. Effect of commonly used drugs in the clinics on HORAS5 expression and selection of cabazitaxel. (A–D) qPCR expression of
HORAS5 and reported cMAX and experimental concentrations upon treatment with enzalutamide (LNCAP, (A), carboplatin (DU145-OE,
(B) and cabazitaxel (LNCAP) [C]; DU145-OE, [D]) drugs on LNCaP AR+ and DU145 AR- PCa cell lines for 72 h. Results expressed as
means ± SD from two independent replicates. One-way ANOVA with Tukey’s post-test was performed for statistical comparison**p =
0.0061, ****p < 0.0001. (E & F) Expression of HORAS5 at different concentrations and different time points of cabazitaxel treatment in
LNCAP (E) and DU145-OE (F). Results expressed as means ± SD from two independent replicates. Two-way ANOVA with Sidak’s post-test
was performed for statistical comparison ****p < 0.0001.
DMSO: Dimethyl sulfoxide; PCa: Prostate cancer; qPCR: Quantitative PCR; SD: Standard deviation.
1B). These results demonstrate that HORAS5 promotes the survival of both AR+ and AR- CRPC cells exposed
to cabazitaxel. In order to investigate the role of the apoptotic pathway in this phenomenon, we measured caspase
3/7 activity in LNCaP and DU145 cells exposed to cabazitaxel. Our data showed that HORAS5 overexpression
significantly reduced caspase 3/7 activation in response to cabazitaxel exposure (Figure 3E). In keeping with this
result, HORAS5 KD increased caspase 3/7 activation in LNCaP cells exposed to cabazitaxel (Figure 3F). Overall,
these findings indicated that HORAS5 promoted cabazitaxel resistance in both AR+ and AR- PCa cells via increase
of cell proliferation and inhibition of caspase-mediated apoptosis.
BCL2A1 expression is induced by cabazitaxel & increased with HORAS5 expression
To evaluate the transcriptomic profile of CRPC cells exposed to cabazitaxel and the effects of HORAS5 modulation,
we performed an NGS transcriptome analysis (Supplementary Figure 2A–E) using the following samples: DU145-
NC, untreated; DU145-NC, exposed to cabazitaxel; DU145-OE, untreated; DU145-OE, exposed to cabazitaxel.
Based on this analysis, 87 genes were significantly upregulated (fold change (FC) ≥2, p < 0.01) in DU145-OE
treated with cabazitaxel versus untreated cells (Figure 4A). Notably, these genes were not significantly upregulated in
DU145-NC exposed to cabazitaxel (Figure 4A). We then ranked these 87 genes according to the DU145-NC p-value
and shortlisted the top 25 (Figure 4A, Supplementary Table 1). Three of these 25 genes (SOX9, CCL20, BCL2A1)
have been previously implicated in cancer and drug resistance (Figure 4 [45–49]A). Hence, we sought to validate our
transcriptome results by measuring the expression of SOX9, CCL20 and BCL2A1 via RT-qPCR. No significant
differences in SOX9 expression were found (Figure 4B). CCL20 and BCL2A1 were both significantly upregulated in
the HORAS5 expressing cells versus negative control upon cabazitaxel exposure. This differential expression pattern
was particularly significant for BCL2A1 (Figure 4C & D), which is also a well described antiapoptotic gene [48,50,51].
For this reason, we decided to investigate the role of BCL2A1 in HORAS5-dependent cabazitaxel resistance. First,
we confirmed that BCL2A1 protein expression was induced by cabazitaxel treatment (Figure 4E). According to our
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Figure 3. HORAS5 silencing and overexpression affect prostate cancer cells proliferation and survival under cabazitaxel exposure. (A–D)
DU145 (A) and LNCaP (B) cell count upon 48 h (DU145) and 72 h (LNCaP) of cabazitaxel treatment, with HORAS5 overexpression and
silencing respectively, compared with the respective negative controls, and resulting IC50s ([C], DU145; [D], LNCaP); cell count is expressed
as nonlinear fit curves of the cell number in percentage normalized to the untreated (DMSO) control. Two-way ANOVA with Sidak’s
post-test was performed for statistical comparison *p = 0.0230, ***p < 0.0005, ****p < 0.0001 and nonlinear fit was used to calculate the
IC50s. Student’s t-test was used in (C & D). (E & F) Caspase 3/7 activity normalized to relative cells number 48 h after cabazitaxel treatment
(DU145) and 48 h post-transfection of HORAS5-siRNA + 72 h after cabazitaxel treatment (LNCaP). One-way ANOVA with Tukey’s post-test
was used in (E & F). for statistical comparison ****p < 0.0001. Results expressed as means ± SD from three independent replicates.
DMSO: Dimethyl sulfoxide; SD: Standard deviation.
results BCL2A1 seemed to be the most consistently upregulated gene in cabazitaxel-treated cells that overexpress
HORAS5. Therefore, we investigated whether BCL2A1 KD could rescue the drug-resistant phenotype induced by
HORAS5 overexpression.
Knockdown of BCL2A1 decreases cell proliferation & increases apoptosis in CRPC cells exposed to
cabazitaxel treatment
Based on our transcriptomic analysis, we hypothesized that BCL2A1 mediates the drug-resistance phenotype
induced by HORAS5. To test this hypothesis, we optimized the KD procedure using two different siRNAs directed
against both variants of BCL2A1 mRNA. Our results show that siRNA1 and siRNA2 determined a reduction
in BCL2A1 mRNA of 84 and 95% respectively (Figure 5A). Our results also showed that both siRNAs reduced
the expression of BCL2A1 protein (Figure 5B). These two siRNAs were used to transfect DU145-OE cells in
order to investigate whether BCL2A1 KD could revert the cabazitaxel resistance phenotype induced by HORAS5
overexpression. Our data showed that BCL2A1 KD significantly reduced DU145-OE resistance to cabazitaxel
(Figure 5C). We also tested whether BCL2A1 effect on cabazitaxel response was a consequence of its antiapoptotic
activity. As we showed in Figure 5D, BCL2A1 KD determined a small increase in apoptosis in untreated cells
(Figure 5D). However, BCL2A1 KD caused a highly significant increase in apoptosis when the cells are exposed to
both 5 nM (1.98≤FC≤2.21, p < 0.0001) and 50 nM (3.06≤FC≤4.36, p < 0.0001) cabazitaxel. These findings
show that BCL2A1, which is upregulated upon HORAS5 expression, enhances cabazitaxel resistance by inhibiting
the apoptosis response.
Translational research: ASO directed against HORAS5 can decrease cabazitaxel IC50 & implications
of HORAS5 expression for the clinics
Since HORAS5 modulation via lentiviral-driven overexpression and siRNA-mediated KD affected cabazitaxel
resistance, we investigated HORAS5 expression in clinical PCa samples from a published study [34], accessed via
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Figure 4. BCL2A1 is the most consistently upregulated gene in prostate cancer cells with HORAS5 overexpression and is induced by
cabazitaxel. (A) Flow chart showing the method used to shortlist cabazitaxel-driven genes in PCa cells that overexpress HORAS5
(DU145-OE vs DU145-NC) from RNA sequencing. (B–D) qPCR validation of the three shortlisted genes: SOX9, CCL20 and BCL2A1. (E)
BCL2A1 expression is significantly increased at the protein level upon cabazitaxel treatment in the cells that overexpress HORAS5
(DU145-OE). Results expressed as means ± SD from four independent experiments in (B–D). One-way ANOVA with Tukey’s post-test was
used in for statistical comparison *p = 0.049, **p < 0.002, ****p < 0.0001.
DMSO: Dimethyl sulfoxide; PCa: Prostate cancer; SD: Standard deviation.
cBioPortal. HORAS5 expression was significantly higher (p = 0.0086) in metastatic samples from patients treated
with taxanes than in untreated patients (Figure 6A). Given this evidence, we analyzed if HORAS5 could effectively
be silenced using ASOs. Since ASOs are currently used in clinical trials [52–54], we thought that this set of experiments
could highlight the therapeutic potential of targeting lncRNAs like HORAS5 in the clinical setting. For this set
of experiments, we used LNCaP cells, which express endogenous detectable levels of HORAS5. We tested eight
different ASOs and found that ASO3 was the most effective inhibitor of HORAS5 expression (78.2%) (Figure 6B,
Supplementary Figure 3). Hence, we tested ASO3 in combination with cabazitaxel to analyze if this HORAS5-
targeting ASO influenced cabazitaxel IC50. Our results showed that the HORAS5-targeting ASO determined a
decrease in the cell count upon cabazitaxel treatment and therefore a significant decrease in the IC50 (FC = 6.55,
p = 0.0034) (Figure 6C & D). To rule out off-target effects, we have tested ASO3 in DU145-NC cells, which
express undetectable levels of HORAS5. ASO3 does not affect HORAS5 expression (Supplementary Figure 5A)
neither cabazitaxel effect on cell count of DU145-NC (Supplementary Figure 5B). This evidence showed that
ASO-directed HORAS5 KD decreased cabazitaxel resistance in LNCaP cells and that its role in vivo should be
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Figure 5. BCL2A1 silencing decreases cell proliferation and increases apoptosis in castration-resistant prostate cancer cells exposed to
cabazitaxel. (A & B) BCL2A1 expression is significantly reduced at the mRNA (A) and protein (B) level upon knockdown (GAPDH was used
as western blot loading control). (C) Cell count upon cabazitaxel treatment, with BCL2A1 KD in cells that overexpress HORAS5
(DU145-OE); cell count is expressed as percentage normalized to the untreated (DMSO) control. (D) Caspase 3/7 activity normalized to
relative cell number in DU145-OE cells upon 48 h BCL2A1 KD + 48 h of cabazitaxel treatment. Results expressed as means ± SD from three
independent replicates. One-way ANOVA with Tukey’s post-test was used in for statistical comparison *p < 0.05, **p < 0.01, ***p <
0.001, ****p < 0.0001. western blots are visualized using Syngene Genesys software.
DMSO: Dimethyl sulfoxide; KD: Knockdown; SD: Standard deviation; WB: western blot.
further evaluated. Overall, these findings suggested that HORAS5 could have a clinical relevance and paved the
way to HORAS5 targeting in combination with taxanes to increase drug response in CRPC patients.
Discussion
CRPC is an incurable malignancy [4], therefore there is an urgent need to find novel diagnostic and prognostic
biomarkers and effective therapeutic targets. Recent findings showed that lncRNAs can have a determinant role in
drug response pathways in some cancers [13,17–21]. Therefore, we hypothesized that lncRNAs may act as promoters
of CRPC aggressive phenotypes.
Our previous work showed that the lncRNA HORAS5 (i.e., linc00161) was upregulated in CRPC PDXs
and increased the survival of AR+ CRPC cells [22], while a previous study showed that HORAS5 decreased
the survival of cisplatin-treated osteosarcoma cells [13]. Based on other studies showing the multifaceted roles of
lncRNAs in different cancers [13,21,55–57], we investigated if this particular lncRNA was involved in drug response
in CRPC, using a panel of clinically used drugs at achievable concentrations [41–44] (see drug treatments section
in Materials & methods). In this study, we have shown for the first time a specific cabazitaxel-driven induction
of HORAS5 expression, using our new model of CRPC cells with lentiviral-induced HORAS5 overexpression
(Figure 7). Cabazitaxel is clinically approved for the treatment of advanced CRPCs that acquired resistance to
docetaxel [8,37,38,58]. So far, there is no evidence implicating lncRNAs in cabazitaxel response.
Since we had already characterized HORAS5 in untreated AR+ cells and targeted it with siRNAs [22], we wanted
to investigate if HORAS5 overexpression changed or maintained the endogenous subcellular localization. While
cytoplasmic molecules are easier to target, nuclear membrane-crossing carriers are needed for nuclear targets.
LncRNA subcellular localization can also be predictive of its putative mechanism of action. Indeed, lncRNAs are
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Figure 6. Clinical relevance of HORAS5: antisense oligonucleotide-mediated inhibition to decrease cabazitaxel
resistance and expression in clinical samples. (A) HORAS5 expression from patients’ metastatic samples treated with
taxanes-only compared with untreated. (B) HORAS5 expression was significantly reduced upon treatment with our
specifically designed ASO (ASO3) (A). (C & D) HORAS5 KD mediated by ASO3 (48 h) induced a decrease in the cell count
upon cabazitaxel treatment (72 h) (C) and a reduction in the IC50 (D). Cell count is expressed as nonlinear fit curves of
the cell number in percentage, normalized to the untreated (DMSO) control. Results expressed as means ± SD from
three independent replicates. Two-way ANOVA with Sidak’s post-test was performed for statistical comparison **p =
0.0056. Student’s t-test was used for statistical comparison in (A) and (D) **p = 0.0081 and p = 0.0034.
DMSO: Dimethyl sulfoxide; KD: Knockdown; SD: Standard deviation.
often found to interact with miRNAs as competing endogenous RNAs when they act in the cytoplasm. Other
studies have shown that lncRNAs can act also in the nucleus via interaction with protein complexes such as
epigenetic and splicing factors [59–61]. Since our data indicated that HORAS5 overexpression promoted a mainly
cytoplasmic localization pattern, we hypothesized that it could be effectively targeted and that it could interact with
cytoplasmic molecules and complexes [62,63].
Our data show that HORAS5 overexpression increases cabazitaxel resistance via regulation of apoptotic signals.
This is consistent with previous studies implicating lncRNAs as regulators of cell apoptosis [64,65] and as mediators
of drug resistance [66,67]. In AR+ PCa cell, HORAS5 acts mainly by stabilizing the AR mRNA, thereby activating
AR-target genes, such as the oncogenic KIAA0101 [22]. Since the AR pathway is a main mediator of taxane
resistance [68–70], this mechanism of action explains the increased cabazitaxel sensitivity of LNCaP cells upon
HORAS5 KD. However, our data on DU145 cells indicate that HORAS5 could mediate taxane-resistance via
AR-independent mechanisms. Hence, we decided to investigate additional HORAS5 mechanisms of action in AR-
cells. From NGS transcriptome analysis, BCL2A1 resulted as the most differentially HORAS5-upregulated gene
upon cabazitaxel treatment. BCL2A1 encodes for an antiapoptotic factor [48,50,51] already described to participate
in drug resistance phenotypes [48,49,71]. Currently there are no studies which implicate BCL2A1 in cabazitaxel
response. Hence, we evaluated the effect of BCL2A1 KD on the drug-resistant phenotype induced by HORAS5
overexpression. Our system efficiently silenced BCL2A1 in untreated PCa cells (KD efficiency 90%). However,
in these conditions we did not observe a striking cell count reduction. This could be attributed to the fact that
BCL2A1 levels are relatively low in untreated PCa cells. However, in the presence of cabazitaxel, BCL2A1 levels
are highly increased. In these conditions, we observed an additive effect between BCL2A1 KD and cabazitaxel
treatment. Taken together, our data indicate that BCL2A1 facilitates the drug-resistance phenotype induced by
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Figure 7. Diagram summarizing our findings. Castration-resistant prostate cancer cells treated with cabazitaxel show upregulation of
HORAS5 that could happen via HORAS5 gene transcriptional activation or degradation inibhition. HORAS5 upregulation increases
BCL2A1 expression and this decreases apoptosis and increases cell proliferation. In response to cabazitaxel treatment, this pathway
enhances drug resistance. When HORAS5 is inhibited via a specifically designed ASO, HORAS5 levels highly decrease causing a decrease in
cabazitaxel resistance.
HORAS5 by promoting AR- CRPC cell survival (Figure 7). Although the specific mechanism by which HORAS5
and BCL2A1 interact needs to be clarified by further studies, we suggest that HORAS5 could sequester one or more
miRNAs which inhibit BCL2A1 translation. For example, mir-128 has been shown to bind HORAS5 in ovarian
cancer cells [21]. Interestingly, BCL2A1 is one of the predicted targets of this miRNA. Moreover, in line with our
previous findings on HORAS5 mechanism of action in AR+ LNCaP cells [22], we also suggest that HORAS5 could
directly interact with BCL2A1, thereby stabilizing and protecting its mRNA. In keeping with this hypothesis, our
in silico predictions suggested that HORAS5 and BCL2A1 have common miRNA-binding sites. Finally, we would
like to point out that the BCL2A1-dependent mechanism of action characterized in this study is likely one of
several ways by which HORAS5 mediates taxane resistance in AR- cells. Our transcriptomic data identified also
other genes potentially regulated by HORAS5, such as the top 25 genes reported in Supplementary Table 1. This
is in line with the pleiotropic mechanism of action displayed by other lncRNAs [72].
We have also shown that HORAS5 overexpression in untreated AR- PCa cells does not affect cellular features
such as cell shape and proliferation. This observation seems to be in contrast with our previous study, which
showed that HORAS5 KD decreases AR+ PCa growth and survival [22]. This discrepancy could be explained by
the different gene modulating approaches employed (transient silencing vs stable overexpression) and by the fact
that HORAS5 seems to act via different mechanisms in AR+ and AR- PCa cells: activation of the AR-pathway
in the former, upregulation of BCL2A1 and other antiapoptotic genes in the latter (particularly in response to
proapoptotic stimuli).
Conclusion
Our findings highlight the potential of HORAS5 in translational studies. The clinical relevance of HORAS5
was assessed by our analyses on database’s available data [34]. Indeed, we have shown that HORAS5 is significantly
upregulated in PCa metastatic samples from patients treated with taxanes compared with taxane-untreated patients.
Moreover, the possibility to detect HORAS5 in biological fluids (i.e., urine and blood) could pave the way for the
use of this lncRNA as noninvasive biomarker for treatment response as well as novel therapeutic target for CRPC. In
this context, we designed a specific antisense molecule (ASO3) capable of effectively inhibiting HORAS5 expression
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in vitro, thereby reducing cabazitaxel resistance in CRPC cells (Figure 7). We would like to point out that our
silencing experiments reduced the chance of off-target effects in many ways: both IDT siRNAs and ASOs were
designed to uniquely match HORAS5 sequence; we used appropriate negative controls at each step; we used two
different silencing methods, obtaining very similar results. Hence, we are confident that the phenotypic effects
observed in this study are uniquely attributable to the silencing of HORAS5.
Since ASOs have been successfully employed in clinical trials [52–54], the use of HORAS5 ASOs in combination
with cabazitaxel could increase CRPC patients’ drug sensitivity and their survival. Therefore, our findings could
bring novel insights in the fields of personalized medicine and innovative diagnostic strategies.
Future perspective
HORAS5 is a lncRNA upregulated in different cancers, including CRPC. It has been recently shown that HORAS5
promotes drug resistance in ovarian cancer. Our work revealed the role of HORAS5 in CRPC drug resistance
and identified a mechanism of action by which HORAS5 inhibits cabazitaxel-induced apoptosis. In light of this
evidence, we proposed a novel approach (ASO-mediated gene silencing) to inhibit this oncogenic lnRNA. This
approach could be used in vivo in future studies and in clinical trials. In the next steps of this work, we plan to
test HORAS5-targeting ASOs using in vivo cancer models. We also plan to further investigate HORAS5 expression
in clinical samples, especially in biological fluids in order to clarify HORAS5 potential as a noninvasive biomarker
for cancer diagnosis and treatment response monitoring. With this future perspective, we are planning to collect
urine and plasma samples from PCa patients, before and after treatment with cabazitaxel and to treat CRPC animal
models with cabazitaxel and HORAS5-ASO combination treatments. Moreover, further mechanistic studies on
HORAS5 action in this context will give more insights on the interaction of HORAS5 with BCL2A1 and other
molecules, paving the way for the discovery of novel molecular pathways and additional targets to reduce cabazitaxel
resistance and increase patient survival.
Summary points
• Since HORAS5 was upregulated in castration-resistant prostate cancer (CRPC) patient-derived xenografts
according to our previous publication, we evaluated if HORAS5 was involved in treatment resistance.
• We showed that HORAS5 expression was highly increased upon cabazitaxel treatment in both AR+ and AR- CRPC
cells.
• HORAS5 knockdown and overexpression affected cabazitaxel response, suggesting that HORAS5 promoted
resistance to this drug by increasing cells proliferation and inhibiting caspase-mediated apoptosis.
• We found that HORAS5 upregulated the antiapoptotic factor BCL2A1.
• BCL2A1 knockdown reverted cabazitaxel resistance phenotype promoted by HORAS5 overexpression in AR- CRPC
cells. This finding confirmed that HORAS5 promoted cabazitaxel resistance by upregulating BCL2A1, thereby
inhibiting drug-induced apoptosis.
• HORAS5 was found upregulated in taxane-treated clinical samples; this finding emphasizes the translational
potential of inhibiting HORAS5.
• Due to these findings, HORAS5 expression was successfully inhibited in CRPC cells, using antisense
oligonucleotides that can be used in future clinical studies. One of our HORAS5 targeting antisense
oligonucleotides decreased cabazitaxel IC50 showing reduction of HORAS5-induced drug resistance.
Supplementary data
To view the supplementary data that accompany this paper please visit the journal website at:
www.futuremedicine.com/doi/suppl/10.2217/epi-2019-0316
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